key: cord-0861146-2aa9l9ij authors: Landtblom, Anne‐Marie; Berntsson, Shala G.; Boström, Inger; Iacobaeus, Ellen title: Multiple sclerosis and COVID‐19: The Swedish experience date: 2021-05-24 journal: Acta Neurol Scand DOI: 10.1111/ane.13453 sha: ee925a8aaa787c9f8500a2e0ae6d0d3eee9162c9 doc_id: 861146 cord_uid: 2aa9l9ij The COVID‐19 pandemic has brought challenges for healthcare management of patients with multiple sclerosis (MS). Concerns regarding vulnerability to infections and disease‐modifying therapies (DMTs) and their complications have been raised. Recent published guidelines on the use of DMTs in relation to COVID‐19 in MS patients have been diverse between countries with lack of evidence‐based facts. In Sweden, there exists a particular interest in anti‐CD20 therapy as a possible risk factor for severe COVID‐19 due to the large number of rituximab‐treated patients off‐label in the country. Rapid responses from the Swedish MS Association (SMSS) and the Swedish MS registry (SMSreg) have resulted in national guidelines on DMT use for MS patients and implementation of a COVID‐19 module in the SMSreg. Recently updated guidelines also included recommendations on COVID‐19 vaccination with regard to the different DMTs. Social distancing policies forced implementation of telemedicine consultation to replace in‐person consultations as part of regular MS health care. Patient‐reported outcome measures (PROMs) in SMSreg have been useful in this respect. This paper reports our experiences on the progress of national MS health care during the COVID‐19 pandemic, in addition to offering an overview of the present scientific context. The aberrant regulation of immune responses in Multiple Sclerosis (MS) does not appear to have any prominent effect on host protection against infections, bacterial or viral. 1 However, there are studies on MS patients that report a higher frequency of infections compared with the general population. [2] [3] [4] Also, an increased risk of hospitalization due to infections has been reported and infections are a common cause of death amongst the MS population. 5, 6 Further on, infections may trigger relapses in MS, which can cause permanent disabilities. 7, 8 Importantly, infections are well-known complications of some MS disease-modifying therapies (DMTs). [9] [10] [11] [12] With regard to previous data, the appearance of a new virus has introduced challenging questions on the definition of risk within the MS population. The neuroinvasive properties of coronaviruses and the detection of COVID-19 virus in the brain of infected patients have raised the question of whether hypoxia/ hypoventilation might be caused by a failed central regulation of the breathing function. 13, 14 It has been suggested that COVID-19 enters the brain through the olfactory mucosa in the nasal cavity where it migrates through olfactory axons to other parts of the brain including the respiratory centre. Furthermore, recent autopsy studies detected a presence of COVID-19 RNA in the epithelial cells of the choroid plexus and ependymal cells in one patient with MS and in a control patient, both of whom died from COVID-19 pneumonia. 15 Viral transcripts were not detected in the brain parenchyma and there were no signs of reactivation of MS lesions suggesting that the blood-brain barrier may play a role for COVID-19 CNS entry. 15 Viral presence in the CNS may also be involved in COVID-19 associated acute respiratory dysfunction syndrome (ARDS). Given these facts, one may ask; does COVID-19 infection confer specific consequences for patients diagnosed with immune-mediated CNS diseases, such as MS? Population-based studies on the incidence of COVID-19 in MS patients compared to the general populations are still rare. A Scottish study reported similar rates of COVID-19 infection in MS patients, compared to the general population. 16 Similarly, the incidence of COVID-19 in Brazilian MS patients was comparable to that of the general population. 17 Accumulating registry and cohort studies have identified neurological disability as an independent clinical risk factor for a more severe COVID-19 disease course. 16, [18] [19] [20] In addition, progressive disease course and longer disease duration were reported as predictors for a worse COVID-19 outcome. 19, 20 The general risk factors old age, male gender and obesity have been confirmed as risk factors also in MS patients. 16,18-21 It is probable that immunomodulatory therapies may affect COVID-19 disease outcome. To date, several studies have suggested that anti-CD20 therapy may be a risk factor for severe COVID-19. International merged data from 28 countries (including Sweden), found a positive correlation between anti-CD20 treatment and risk for hospital care and intensive care in 2340 MS patients with COVID-19 infection. 22 Accordingly, a study from Italy, including 844 MS patients, showed that those treated with anti-CD20 therapy carried a two to threefold risk increase of severe COVID-19 infection. 19 Furthermore, a North American registry-based study of 1626 MS patients with COVID-19 described an increased risk for hospitalization in patients treated with rituximab (4.5 fold increase) compared to patients without DMTs. 23 Langer-Gould et al. 24 specifically studied MS patients with rituximab therapy and demonstrated that this group of patients had an increased risk for hospitalization if infected with COVID-19, compared to the general population. This study also showed that shorter time frame post rituximab infusion was arisk factor for severe COVID-19. 24 French registry data including nearly 350 MS patients indicated no association between exposure to DMTs and the severity of COVID-19, but sub-analysis of anti-CD20 therapy was not presented. 20 In addition, registry data of 129 MS patients from 15 Latin American countries demonstrated no association between COVID-19 severity and any DMT. 18 A report on safety data from Roche / Genentech, April 2020, showed that 26 out of 74 cases with confirmed COVID-19 infection in ocrelizumabtreated MS patients were hospitalized, and at least 12 were classified as critical/ serious. 25 The most severely affected COVID-19 patients with multi-organ failure have been found with massive immunological hyperactivation and severe cytokine release. Given that the impact on lung function during COVID-19 infection resembles ARDS, which is caused by an overactive immune system, immunologically tailored treatments could be a viable potent option. This hypothesis has been supported by recent preliminary results of improved clinical outcome in COVID-19 patients treated with the interleukin-6 inhibitor tocilizumab. 26 The link to current MS immunomodulatory drugs is of interest, as some of these drugs may even be beneficial in COVID-19. A recent study showed that combination therapy with interferon beta-1b, lopinavir, ritonavir and ribavirin improved clinical outcome in COVID-19 infection, maybe secondary to antiviral effects of beta interferon. 27 In line with the aforementioned, data analyses from US electronic health records of approximately 30 000 MS patients showed that treatment with beta interferons or glatiramer acetate was associated with a lower risk of contracting COVID-19, compared to those treated with other DMTs. 28 Another example of interest in antiviral effects is the current clinical trials of fingolimod as a treatment for ARDS in COVID-19. 29 Further, a potential positive effect correlated with the selective blocking of adhesion molecules mediated by natalizumab, has been proposed as the virus might use integrins, in addition to the ACE2 receptor, for cell entry. 30 On the other hand, blocking CNS lymphocyte entry could be problematic in relation to the risk for COVID-19 encephalitis. The properties of teriflunomides to induce tolerogenic immune cell profiles and possible anti-viral effects have been highlighted as potentially beneficial in preventing hyperinflammation in complicated COVID-19 infection. 31 A study on COVID-19 in teriflunomide-treated MS patients reported mild disease courses in patients that continued DMT treatment during the active infection. 31 It has also been discussed whether the mechanisms of action of dimethyl fumarate may confer protective effects against severe COVID-19 infection. However, the potency of this drug is complicated by the risk of lymphopenia which is a well-recognized side effect. Mild courses of COVID-19 disease, without the need for hospitalization, were reported in seven dimethyl fumarate-treated MS patients in Italy, of whom only one had lymphopenia. 32 The immunosuppressive mechanisms of high-effective DMTs do most likely hamper the development of effective immune responses against vaccines. 33 It is recognized that it takes at least four weeks to acquire an initial optimal antibody response and a couple of months fumarates. 33, 34 Adequate seroprotection after vaccination for influenza H1N1, H3N2 and B antigens has been observed in one study on teriflunomide-treated MS patients. 35 A few reports indicate that fingolimod reduces immune responses to certain vaccines. 36, 37 Olberg et al. showed diminished seroprotection after seasonal influenza vaccination in MS patients receiving fingolimod or natalizumab while another study showed sufficient humoral response to influenza vaccine in natalizumab-treated patients. 38, 39 Reduced antibody production after vaccination against pneumococcal and tetanoid vaccine 12 weeks after initiation of ocrelizumab in MS patients has been reported. 40 The same study also showed absence of protective immune response to vaccination with a new antigen in ocrelizumab treated individuals. 41 DMTs are currently prescribed to approximately 10,000 MS patients in Sweden, most of whom do not have severe disabilities that affect the respiratory system. According to SMSS guidelines (as of 5 January 2021), interferon beta, glatiramer acetate and teriflunomide are classified as 'possible non-risk' therapies for severe COVID-19. Other therapies such as dimethyl fumarate (without lymphopenia), natalizumab, fingolimod, siponimod are considered to mediate a 'possible low risk'. Cladribine is also considered as 'possible low risk' therapy but increased infection control precaution is recommended within 2-3 months following drug administration. Immune reconstitution therapies including alemtuzumab and AHSCT pose 'a possible increased risk' for severe COVID-19 in patients up to two years after AHSCT and alemtuzumab, provided that the B and T lymphocyte counts are normalized. Considerable attention has been given to rituximab, which at present is the most commonly prescribed DMT for MS patients in Sweden (Figure 1 ). It should be noted that rituximab is prescribed off-label in Sweden at a much higher rate compared to other nations. 49 In the earliest recommendations from SMSS, rituximab and other anti-CD20 therapies were considered to entail a 'possible increased risk'. Rituximab had previously been associated with a higher incidence of respiratory infections in MS patients compared to other DMTs. 12 The original classification remains in the lat- infection/vaccine response is recommended for each MS patient. Following the Swedish National Board of Health and Welfare's initial statement that MS patients constitute a risk group, requests about the adaption of work tasks and the possibility to work from home were raised from patients. 45 The patients were advised to reach agreements with their respective employers about possible workrelated changes to favour work from a distance and temporary sick leave has been applied in a few specific cases. In spring 2020, the National Board of Health and Welfare announced that a preventive sickness compensation ('smittskyddspenning'), as part of Swedish Social Insurance, was to be established for patients in risk groups. In summer 2020, the government announced approval of an amended COVID-19 budget to reimburse patients belonging to risk groups unable to work from home, in terms of temporary sickness compensation. The qualifying period is due at the end of April 2021 and it was recently announced that the requirement for a medical certificate, when applying for sickness compensation, has temporarily been removed. Sickness compensation can also be obtained by relatives who are obliged to refrain from work in order to avoid infecting a close relative who belongs to a risk group. In the event of confirmed COVID-19 infection there is also a possibility of disease carrier compensation ('smittbärarpenning'). 55 Major changes in MS patient care have been implemented across Sweden with a focus on telemedicine to replace in-person visits. have reported promising outcomes. 56, 57 Interestingly, a recent study from Norway found that neurologists considered teleconsultations as better suited for patients with headache and epilepsy compared with MS and PD. 58 Furthermore, telephone consultations were regarded as being more professionally suitable for follow-up consultations consistent with the current clinical praxis at MS centres in Sweden. However, future studies assessing patient-reported outcomes related to telemedicine will provide more knowledge on the efficacy of this type of medical care. Recent reports have shown that patients with anti-CD20 therapies have a higher risk of a worse COVID-19 disease course. Taken into account disease type, age, gender, and other host factors, individual risk assessment needs to be applied. Future research on COVID-19- Immunology of Multiple Sclerosis Common comorbidities and survival in MS: Risk for stroke, type 1 diabetes and infections Infections in patients with multiple sclerosis: a national cohort study in Sweden Infections in patients diagnosed with multiple sclerosis: A multi-database study Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation Does upper respiratory infection exacerbate symptoms of multiple sclerosis? Multiple sclerosis treatment and infectious issues: update 2013 Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies Efficacy and safety of the newer multiple sclerosis drugs approved since 2010 Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies Neuroinvasion of SARS-CoV-2 may play a role in the breakdown of the respiratory center of the brain Evidence of SARS-CoV-2 replication and tropism in the lungs, airways and vascular endothelium of patients with fatal COVID-19: an autopsy case-series Presence of SARS-CoV-2 transcripts in the choroid plexus of MS and non-MS patients with COVID-19 Impact of the first COVID-19 pandemic wave on the Scottish Multiple Sclerosis Register population Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM Disease modifying therapies and Covid-19 severity in Multiple Sclerosis Clinical characteristics and outcomes in patients with coronavirus disease 2019 and muliple sclerosis COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response Associations of DMT therapies with COVID-19 severity in multiple sclerosis Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis Multiple sclerosis, rituximab, and COVID-19 COVID-19 in persons with multiple sclerosis treated with ocrelizumab -a pharmacovigilance case series Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role COVID-19 in teriflunomide-treated patients with multiple sclerosis COVID-19 in dimethyl fumaratetreated patients with multiple sclerosis Effects of MS disease-modifying therapies on responses to vaccinations: A review Immune response to vaccines is maintained in patients treated with dimethyl fumarate Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy Humoral immune response to influenza vaccine in natalizumab-treated MS patients Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab Multiple Sclerosis and COVID-19 -Still limited knowledge Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden -outlier or predecessor? Increased rate of hospitalization for COVID-19 amongst Rituximab treated multiple sclerosis patients: a study of the Swedish MS Registry Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases Persistent cellular immunity to SARS-CoV-2 infection The promise of telemedicine for chronic neurological disorders: the example of Parkinson's disease Telemedicine in epilepsy: How can we improve care, teaching, and awareness? Epilepsy Behav Experiences of telemedicine in neurological out-patient clinics during the COVID-19 pandemic Multiple sclerosis and COVID-19: The Swedish experience